Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension

Tatiana M. Ripp, Victor F. Mordovin, Stanislav E. Pekarskiy, Tamara R. Ryabova, Marina V. Zlobina, Andrei E. Baev, Yana Anfinogenova, Sergey V. Popov

Результат исследований: Материалы для журналаОбзорная статья

4 Цитирования (Scopus)

Выдержка

The aims of the study were to evaluate the effects of renal sympathetic denervation (RSD) on the heart and to identify the predictors of RSD efficacy in patients with resistant arterial hypertension. The study comprised 60 RSD patients (54.6 ± 9.5 years) who received full-dose antihypertensive therapy (4.1 drugs) including diuretics. Initially, 58.6 % of patients had abnormal left ventricular (LV) diastolic function. All patients received echocardiography before and 24 weeks after RSD. Renal sympathetic denervation was achieved through the endovascular radiofrequency ablation (RFA) of the renal arteries. Drug therapy continued for the entire period of observation. After RSD, all patients were retrospectively assigned to two groups: group 1 comprised patients (n = 22; 36.7 %) in whom the myocardial mass (MM) of the left ventricle decreased by more than 10 g after RSD; group 2 comprised patients (n = 38; 63.3 %) in whom LV MM increased or decreased by less than 10 g. Anthropometry, arterial blood pressure, heart rate, therapy, and LV end-diastolic dimensions (EDD) were comparable in these groups. After RSD, the values of office blood pressure significantly decreased and MM regressed by more than 10 g in 36.7 % of patients; LV diastolic function normalized in 31 % of patients, and diastolic dysfunction improved in 14 % of patients. The study found the associations between the initial LV wall dimensions and LV MM changes. Unlike LV EDD, arterial blood pressure, or heart rate, the initial values of LV wall thickness predicted LV MM regress. Trial registration: #NCT01499810 https://clinicaltrials.gov/ct2/show/NCT01499810.

Язык оригиналаАнглийский
Номер статьи90
ЖурналCurrent Hypertension Reports
Том17
Номер выпуска12
DOI
СостояниеОпубликовано - 1 дек 2015

Отпечаток

Denervation
Sympathectomy
Hypertension
Kidney
Left Ventricular Function
Arterial Pressure
Heart Rate
Drug Therapy
Anthropometry
Renal Artery
Diuretics
Antihypertensive Agents
Heart Ventricles
Echocardiography
Observation
Blood Pressure

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)

Цитировать

Ripp, T. M., Mordovin, V. F., Pekarskiy, S. E., Ryabova, T. R., Zlobina, M. V., Baev, A. E., ... Popov, S. V. (2015). Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension. Current Hypertension Reports, 17(12), [90]. https://doi.org/10.1007/s11906-015-0603-8

Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension. / Ripp, Tatiana M.; Mordovin, Victor F.; Pekarskiy, Stanislav E.; Ryabova, Tamara R.; Zlobina, Marina V.; Baev, Andrei E.; Anfinogenova, Yana; Popov, Sergey V.

В: Current Hypertension Reports, Том 17, № 12, 90, 01.12.2015.

Результат исследований: Материалы для журналаОбзорная статья

Ripp, TM, Mordovin, VF, Pekarskiy, SE, Ryabova, TR, Zlobina, MV, Baev, AE, Anfinogenova, Y & Popov, SV 2015, 'Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension', Current Hypertension Reports, том. 17, № 12, 90. https://doi.org/10.1007/s11906-015-0603-8
Ripp TM, Mordovin VF, Pekarskiy SE, Ryabova TR, Zlobina MV, Baev AE и соавт. Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension. Current Hypertension Reports. 2015 Дек. 1;17(12). 90. https://doi.org/10.1007/s11906-015-0603-8
Ripp, Tatiana M. ; Mordovin, Victor F. ; Pekarskiy, Stanislav E. ; Ryabova, Tamara R. ; Zlobina, Marina V. ; Baev, Andrei E. ; Anfinogenova, Yana ; Popov, Sergey V. / Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension. В: Current Hypertension Reports. 2015 ; Том 17, № 12.
@article{de3ce947314e4580980dd3867b7a55ed,
title = "Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension",
abstract = "The aims of the study were to evaluate the effects of renal sympathetic denervation (RSD) on the heart and to identify the predictors of RSD efficacy in patients with resistant arterial hypertension. The study comprised 60 RSD patients (54.6 ± 9.5 years) who received full-dose antihypertensive therapy (4.1 drugs) including diuretics. Initially, 58.6 {\%} of patients had abnormal left ventricular (LV) diastolic function. All patients received echocardiography before and 24 weeks after RSD. Renal sympathetic denervation was achieved through the endovascular radiofrequency ablation (RFA) of the renal arteries. Drug therapy continued for the entire period of observation. After RSD, all patients were retrospectively assigned to two groups: group 1 comprised patients (n = 22; 36.7 {\%}) in whom the myocardial mass (MM) of the left ventricle decreased by more than 10 g after RSD; group 2 comprised patients (n = 38; 63.3 {\%}) in whom LV MM increased or decreased by less than 10 g. Anthropometry, arterial blood pressure, heart rate, therapy, and LV end-diastolic dimensions (EDD) were comparable in these groups. After RSD, the values of office blood pressure significantly decreased and MM regressed by more than 10 g in 36.7 {\%} of patients; LV diastolic function normalized in 31 {\%} of patients, and diastolic dysfunction improved in 14 {\%} of patients. The study found the associations between the initial LV wall dimensions and LV MM changes. Unlike LV EDD, arterial blood pressure, or heart rate, the initial values of LV wall thickness predicted LV MM regress. Trial registration: #NCT01499810 https://clinicaltrials.gov/ct2/show/NCT01499810.",
keywords = "Diastolic function, Echocardiography, Heart, Hypertension, Left ventricular hypertrophy, Renal denervation, RSD",
author = "Ripp, {Tatiana M.} and Mordovin, {Victor F.} and Pekarskiy, {Stanislav E.} and Ryabova, {Tamara R.} and Zlobina, {Marina V.} and Baev, {Andrei E.} and Yana Anfinogenova and Popov, {Sergey V.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11906-015-0603-8",
language = "English",
volume = "17",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension

AU - Ripp, Tatiana M.

AU - Mordovin, Victor F.

AU - Pekarskiy, Stanislav E.

AU - Ryabova, Tamara R.

AU - Zlobina, Marina V.

AU - Baev, Andrei E.

AU - Anfinogenova, Yana

AU - Popov, Sergey V.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The aims of the study were to evaluate the effects of renal sympathetic denervation (RSD) on the heart and to identify the predictors of RSD efficacy in patients with resistant arterial hypertension. The study comprised 60 RSD patients (54.6 ± 9.5 years) who received full-dose antihypertensive therapy (4.1 drugs) including diuretics. Initially, 58.6 % of patients had abnormal left ventricular (LV) diastolic function. All patients received echocardiography before and 24 weeks after RSD. Renal sympathetic denervation was achieved through the endovascular radiofrequency ablation (RFA) of the renal arteries. Drug therapy continued for the entire period of observation. After RSD, all patients were retrospectively assigned to two groups: group 1 comprised patients (n = 22; 36.7 %) in whom the myocardial mass (MM) of the left ventricle decreased by more than 10 g after RSD; group 2 comprised patients (n = 38; 63.3 %) in whom LV MM increased or decreased by less than 10 g. Anthropometry, arterial blood pressure, heart rate, therapy, and LV end-diastolic dimensions (EDD) were comparable in these groups. After RSD, the values of office blood pressure significantly decreased and MM regressed by more than 10 g in 36.7 % of patients; LV diastolic function normalized in 31 % of patients, and diastolic dysfunction improved in 14 % of patients. The study found the associations between the initial LV wall dimensions and LV MM changes. Unlike LV EDD, arterial blood pressure, or heart rate, the initial values of LV wall thickness predicted LV MM regress. Trial registration: #NCT01499810 https://clinicaltrials.gov/ct2/show/NCT01499810.

AB - The aims of the study were to evaluate the effects of renal sympathetic denervation (RSD) on the heart and to identify the predictors of RSD efficacy in patients with resistant arterial hypertension. The study comprised 60 RSD patients (54.6 ± 9.5 years) who received full-dose antihypertensive therapy (4.1 drugs) including diuretics. Initially, 58.6 % of patients had abnormal left ventricular (LV) diastolic function. All patients received echocardiography before and 24 weeks after RSD. Renal sympathetic denervation was achieved through the endovascular radiofrequency ablation (RFA) of the renal arteries. Drug therapy continued for the entire period of observation. After RSD, all patients were retrospectively assigned to two groups: group 1 comprised patients (n = 22; 36.7 %) in whom the myocardial mass (MM) of the left ventricle decreased by more than 10 g after RSD; group 2 comprised patients (n = 38; 63.3 %) in whom LV MM increased or decreased by less than 10 g. Anthropometry, arterial blood pressure, heart rate, therapy, and LV end-diastolic dimensions (EDD) were comparable in these groups. After RSD, the values of office blood pressure significantly decreased and MM regressed by more than 10 g in 36.7 % of patients; LV diastolic function normalized in 31 % of patients, and diastolic dysfunction improved in 14 % of patients. The study found the associations between the initial LV wall dimensions and LV MM changes. Unlike LV EDD, arterial blood pressure, or heart rate, the initial values of LV wall thickness predicted LV MM regress. Trial registration: #NCT01499810 https://clinicaltrials.gov/ct2/show/NCT01499810.

KW - Diastolic function

KW - Echocardiography

KW - Heart

KW - Hypertension

KW - Left ventricular hypertrophy

KW - Renal denervation

KW - RSD

UR - http://www.scopus.com/inward/record.url?scp=84945194401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945194401&partnerID=8YFLogxK

U2 - 10.1007/s11906-015-0603-8

DO - 10.1007/s11906-015-0603-8

M3 - Review article

C2 - 26482895

AN - SCOPUS:84945194401

VL - 17

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 12

M1 - 90

ER -